Connor, Clark & Lunn Investment Management Ltd. Viridian Therapeutics, Inc.\De Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 9,130 shares of VRDN stock, worth $190,086. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,130Holding current value
$190,086% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding VRDN
# of Institutions
179Shares Held
76.8MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$99.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$92 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$80.8 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$78.1 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$71.7 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $830M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...